Skip to main content

Table 4 Summary of plasma remogliflozin etabonate, remogliflozin, and GSK279782 PK parameters in T2DM subjects a

From: First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

  Remogliflozin etabonate Remogliflozin GSK279782
Remogliflozin etabonate dose 50 mg 500 mg 50 mg 500 mg 50 mg 500 mg
AUC (0–∞) c (ng•h/mL)       
Geometric mean (CV%) 8.91 (58) 91.9 (46) b 523 (38) 5176 (44) 130 (50) 1293 (45)
C max (ng/mL)       
Geometric mean (CV%) 9.56 (39) 83.9 (89) 195 (46) 1891 (49) 34.6 (39) 314 (39)
T max (h)       
Median 0.58 0.75 1.46 2.50 1.74 2.75
(range) (0.33–0.78) (0.33–2.50) (0.33–2.00) (0.33–4.00) (0.75–4.00) (0.75–4.00)
T ½ (h)       
Geometric mean (CV%) 0.61 (32) 0.82 (69) b 1.59 (27) 3.93 (25) 2.05 (24) 3.28 (23)
AUC (0–∞) ratio       
(Remogliflozin/remogliflozin etabonate) Geometric mean (CV%) 59 (62) 54 (38)
  1. a. n = 6 unless otherwise specified.
  2. b. n = 2.
  3. c. The median percentage of AUC(0-∞) extrapolated for remogliflozin etabonate ranged from 10% to 11% and for remogliflozin was low ranging from 0.14% to 0.42% and for GSK279782 was 0.47% to 2.0%.